Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib in Recurrent Glioblastoma
NCT01975701Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2013
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of infigratinib in glioblastoma (GBM), glioma, sponsored by Novartis. Started Dec 2013; status: completed.
02
Drugs
infigratinib
03
Conditions
glioblastoma (GBM)glioma
Beyond the preview
Go deeper on NCT01975701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01975701.